ERBB2 and breast cancer: Evidence has shown that HER2 targeted antibodies induce ADCC by triggering FCγRIII on NK cells and act against HER2pos disease.5 A clinical trial showed that trastuzumab induced ADCC with pCR in patients with HER2pos BC.